# Aflac Inc. (AFL)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/AFL/primer

## Business Model

---
ticker: AFL
step: 01
generated: 2026-05-12
source: quick-research
---

### Aflac Incorporated (AFL) — Business Overview

#### Business Description
Aflac is the #1 supplemental insurance company in the United States and a leading supplemental health/life insurer in Japan. Founded 1955 in Columbus, Georgia. Pioneered cancer insurance in 1958. Two operating segments: Aflac Japan (~70% revenue, focus on cancer + medical insurance) and Aflac U.S. (supplemental health products including accident, disability, dental, vision, hospital indemnity). Branding hallmark: "Aflac duck" mascot.

#### Revenue Model
~$17.2B FY2025 revenue (down 9.3% from $18.9B in 2024) — declined due to net investment losses. Premium revenue (net earned premiums) + net investment income. Predominantly Japan: Aflac Japan generates ~70% of premium income. Lump-sum benefits paid directly to policyholders (not providers) — distinctive market positioning. Highly profitable (~22% ROE).

#### Products & Services
- **Cancer insurance** — Aflac's heritage franchise (pioneered 1958)
- **Medical insurance** — Japan focus (long-term)
- **Accident insurance** — US workplace voluntary benefit
- **Disability insurance** — Short + long-term
- **Dental + Vision** — US workplace
- **Hospital indemnity** — US
- **Long-Term Care** — New hybrid LTC rider launched 2025-26
- **Medical Shield** — New product rollout
- **Aflac Re Bermuda** — Reinsurance subsidiary (Japan Post deal 2026)

#### Customer Base & Go-to-Market
500,000+ independent insurance agents + brokers globally. ~90,000 employer partnerships in US providing supplemental group insurance. Heritage individual + workplace voluntary. Geographic: ~70% Japan + ~30% US. Aging Japanese population + younger US workplace = different demand dynamics.

#### Competitive Position
#1 US supplemental insurance. Japan's largest cancer insurer. Competes with MetLife, Prudential, AIG, Sun Life, Lincoln Financial, Unum (US); Sony Life, Tokio Marine (Japan). Differentiated by: distinctive brand (Aflac duck), lump-sum payments to policyholders, dual-market scale (US + Japan), supplemental specialty rather than core medical.

#### Key Facts
- Founded: 1955 (Columbus, GA, by Amos brothers)
- Headquarters: Columbus, GA
- Employees: ~12,000+
- Exchange: NYSE (AFL)
- Sector / Industry: Financials / Insurance (Life & Health)
- Market Cap: ~$60B
- CEO: Daniel Amos (since 1990, founder's nephew); Chairman
- Long-tenured CEO = 35+ years

## Financial Snapshot

---
ticker: AFL
step: 04
generated: 2026-05-12
source: quick-research
---

### Aflac Incorporated (AFL) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY (25) |
|--------|--------|--------|--------|--------|----------|
| Total Revenue | $19.1B | $18.7B | $18.9B | $17.2B | -9.3% |
| Net Premium Income | $15.0B | $14.6B | $14.0B | $13.4B | -4% |
| Net Investment Income | $3.7B | $3.6B | $3.6B | $3.4B | -6% |
| Adjusted Net Earnings | $5.2B | $5.6B | $5.4B | $3.6B | -33% |
| Diluted EPS | $7.69 | $9.55 | $9.59 | $6.65 | -31% |
| Net Profit Margin | 28.8% | 30.0% | 28.8% | 21.2% | -760bps |
| Annualized ROE | ~14% | ~16% | ~14% | ~22% | |

Note: FY25 net earnings $3.6B reflects net investment losses + increased credit loss allowances. Q4 25 diluted EPS $2.64. Q3 25 annualized adjusted ROE ex-FX = 22.1% — strong core profitability.

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$4.0B |
| Free Cash Flow | ~$3.5B |
| FCF Conversion | ~100% |
| Cash & Equivalents | ~$5.0B |
| Total Debt | ~$8.0B (59% in yen) |
| Investment Portfolio | ~$110B |
| Yen Debt Hedge | Enterprise hedging program

#### Key Ratios (approximate)
- P/E: ~16x | P/B: ~1.7x
- Revenue Growth (TTM): -9.3% | Net Margin: 21.2%
- Dividend Yield: ~2.0% | Dividend Growth: 43 years
- $3.5B 2025 buybacks (~6% of market cap)
- 114.3M shares remaining authorized for repurchase

#### Growth Profile
Japan core earned premiums declining 1-2% (paid-up products + aging population). US supplemental growing low-single-digit. Investment income compounding as portfolio rolls forward. Margin recovery on credit loss normalization. Hybrid LTC rider + Medical Shield new product rollouts. Aflac Re Bermuda + Japan Post deal expand reinsurance optionality.

#### Forward Estimates
- **FY 2026**: Adj EPS ~$7.00-7.50; net premium income +0-1%; ROE ~15-18%
- **FY 2027**: Adj EPS ~$7.50-8.00 with new product traction
- $113 average analyst price target vs ~$103 = ~10% upside
- 43-year dividend growth track record + 5.2% Q1 26 dividend increase

## Recent Catalysts

---
ticker: AFL
step: 12
generated: 2026-05-12
source: quick-research
---

### Aflac Incorporated (AFL) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **22% ROE + 43-year dividend growth + $3.5B annual buybacks** — Q3 2025 annualized adjusted ROE ex-FX = 22.1%. Best-in-class insurance profitability. 43 consecutive years of dividend increases (Dividend Aristocrat). 5.2% Q1 26 dividend increase. $3.5B 2025 buybacks (~6% of market cap). 114M shares remaining authorized = continued capital return.

2. **Dual-market diversification: 70% Japan + 30% US** — Aflac generates ~70% revenue from Japan (largest cancer insurer + brand leader) + 30% US (largest supplemental). US growth offsets Japan demographic decline. Distinctive lump-sum payment model + Aflac duck branding creates moat. Aflac Re Bermuda reinsurance optionality (Japan Post deal 2026).

3. **New product rollouts: Hybrid LTC + Medical Shield** — Hybrid Long-Term Care rider (combines life + LTC) addresses major US market gap. Medical Shield rollout expanding US coverage. Higher tech + distribution spending (some margin pressure) but positions for future growth as insurance market evolves toward simpler supplemental products.

4. **Cash flow conversion + balance sheet quality** — Nearly all operating cash flow converts to free cash flow → substantial returns via buybacks + debt repayment. ~$110B investment portfolio. Yen hedging program protects economic value. Conservative balance sheet supports continued capital return through cycles.

#### Bear Case Risks

1. **Japan demographic decline = structural premium pressure** — Japan's population aging faster than anywhere else; expected to lose 34% by end of century. Japan core earned premiums guided to decline 1-2% in 2026. Older policyholders age out of new product purchases. Insurance demand structurally challenged in Japan despite incumbent leadership.

2. **2025 net margin compressed 28.8% → 21.2%** — Net profit margin moved from 28.8% to 21.2% over the last year. Higher tech + distribution spending not yet translating into margin expansion. Credit loss allowances on investment portfolio increased. If credit cycle worsens, margins compress further.

3. **Yen/USD currency volatility + interest rate sensitivity** — Every 5 yen to dollar move = ~$0.07 EPS impact. ~70% of business in yen-denominated terms. If yen strengthens materially, USD-reported earnings compress. Enterprise hedging program mitigates but doesn't eliminate. Plus interest rate sensitivity on investment portfolio.

4. **Cybersecurity + tech execution risk** — Massive cyberattack in early 2026 raised concerns. Insurance industry highly targeted. Customer data + claim systems disruption risk. Multi-year tech investment program needed but execution complexity high.

#### Upcoming Events

- **Q2 2026 earnings (August 2026)** — Hybrid LTC + Medical Shield traction
- **Q3 2026 earnings (November 2026)** — Mid-year guide reset
- **Aflac Re Bermuda + Japan Post integration** — Reinsurance optionality
- **Yen/USD evolution** — Direct EPS driver
- **Federal Reserve + BoJ rate policy** — Investment income driver

#### Analyst Sentiment

Sell-side consensus is **Hold / Market Perform** with average price target ~$113 vs. recent ~$103 trading levels (~10% upside). Keefe, Bruyette & Woods reinstated Market Perform $113. Bulls cite 22% ROE + 43-yr dividend growth + buybacks + dual-market diversification + new products. Bears focus on Japan demographic + margin compression + yen risk + cyberattack. AFL is widely viewed as a high-quality compounder with structural Japan headwinds + steady capital return.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/afl
- Full research API: GET /api/v1/research/AFL/memo
- Coverage universe: /stocks